Abstract
DH in MCA malignant stroke has been demonstrated to reduce mortality over 50% in the acute phase, determining an increase in moderate-to-severe disability in the surviving patients, as compared to patients receiving medical treatment. In this preliminary analysis we want to evaluate clinical and neuroradiological prognostic indicators in patients with malignant cerebral infarction treated by DH.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.